The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Principles that Govern the Folding of Protein Chains
Anfinsen, C. B. (1973) · Science · doi:10.1126/science.181.4096.223 · Cited by 7,096
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Cited by
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
Bernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G., Teplow, D. B., Shea, J.-E., Ruotolo, B. T., Robinson, C. V., et al. (2009) · Nature Chemistry · doi:10.1038/nchem.247 · Cited by 918
Self-citationParsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
“We note that, apart from its minor amount, the fiber component would be of lesser importance since its toxicity is lower than that of oligomers (Klein et al., 2004; Ono et al., 2009).”
BackgroundMethodDe Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Self-citationBiology of Amyloid: Structure, Function, and Regulation
Greenwald, J., & Riek, R. (2010) · Structure · doi:10.1016/j.str.2010.08.009 · Cited by 575
Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide
Faller, P., & Hureau, C. (2009) · Dalton Trans. · doi:10.1039/b813398k · Cited by 530
Axonal Transport Defects in Neurodegenerative Diseases
Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe, N., Bosco, D. A., Brown, R. H., Brown, H., Tiwari, A., Hayward, L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3463-09.2009 · Cited by 464
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Self-citationAdenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
Hamaguchi, T., Ono, K., Murase, A., & Yamada, M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090417 · Cited by 398
Bowman, G. R., Beauchamp, K. A., Boxer, G., & Pande, V. S. (2009) · The Journal of Chemical Physics · doi:10.1063/1.3216567 · Cited by 396
Aβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Dall'Igna, O. P., Fett, P., Gomes, M. W., Souza, D. O., Cunha, R. A., & Lara, D. R. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.008 · Cited by 372
Wang, J., Ho, L., Zhao, W., Ono, K., Rosensweig, C., Chen, L., Humala, N., Teplow, D. B., & Pasinetti, G. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0364-08.2008 · Cited by 361
Self-citationAβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
“, 2004), an increasing body of evidence suggests that soluble oligomeric and protofibrillar A species, such as A *56, may cause the synaptic dysfunction and memory deficits in mice (Klein et al., 2004; Cleary et al., 2005; Glabe, 2006; Lesne et al., 2006).”
BackgroundAlzheimer’s pathogenesis: is there neuron-to-neuron propagation?
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0825-z · Cited by 359
Canas, P. M., Porciúncula, L. O., Cunha, G. M. A., Silva, C. G., Machado, N. J., Oliveira, J. M. A., Oliveira, C. R., & Cunha, R. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3728-09.2009 · Cited by 357
Oxidative stress in neurodegenerative diseases.
Chen, X., Guo, C., & Kong, J. (2012) · PubMed · doi:10.3969/j.issn.1673-5374.2012.05.009 · Cited by 356
Finder, V. H., & Glockshuber, R. (2007) · Neurodegenerative Diseases · doi:10.1159/000100355 · Cited by 348
Competing Pathways Determine Fibril Morphology in the Self-assembly of β2-Microglobulin into Amyloid
Gosal, W. S., Morten, I. J., Hewitt, E. W., Smith, D. A., Thomson, N. H., & Radford, S. E. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.06.040 · Cited by 343
Amyloid β-Protein: Monomer Structure and Early Aggregation States of Aβ42 and Its Pro19Alloform
Bernstein, S. L., Wyttenbach, T., Baumketner, A., Shea, J.-E., Bitan, G., Teplow, D. B., & Bowers, M. T. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044531p · Cited by 341
Self-citationA toxic monomeric conformer of the polyglutamine protein
Nagai, Y., Inui, T., Popiel, H. A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H., & Toda, T. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1215 · Cited by 333
On the nucleation of amyloid β‐protein monomer folding
Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C., & Teplow, D. B. (2005) · Protein Science · doi:10.1110/ps.041292205 · Cited by 331
Self-citationTemporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298
Self-citationResveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y., Wang, X.-P., Yang, S.-G., Wang, Y.-J., Zhang, X., Du, X.-T., Sun, X.-X., Zhao, M., Huang, L., & Liu, R.-T. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 295
Walsh, D. M., Townsend, M., Podlisny, M. B., Shankar, G. M., Fadeeva, J. V., Agnaf, O. E., Hartley, D. M., & Selkoe, D. J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4391-04.2005 · Cited by 286
Faller, P. (2009) · ChemBioChem · doi:10.1002/cbic.200900321 · Cited by 285
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
Self-citationGuilloreau, L., Combalbert, S., Sournia‐Saquet, A., Mazarguil, H., & Faller, P. (2007) · ChemBioChem · doi:10.1002/cbic.200700111 · Cited by 270
Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
O'Nuallain, B., Freir, D. B., Nicoll, A. J., Risse, E., Ferguson, N., Herron, C. E., Collinge, J., & Walsh, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3537-10.2010 · Cited by 259
Hureau, C., & Faller, P. (2009) · Biochimie · doi:10.1016/j.biochi.2009.03.013 · Cited by 259
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
Methylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165
“The major neuropathological lesions of AD include intracellular neurofibrillary tangles, which are paired helical filaments of hyperphosphorylated tau proteins, extracellular deposits of fibrillar amyloid-β (Aβ) peptide in senile plaques, and the buildup of soluble Aβ oligomers [1, 2].”
BackgroundAlzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., Bredesen, D. E., Koo, E. H., Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5032fje · Cited by 132
Chen, K., Maley, J., & Yu, P. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04181.x · Cited by 131
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
“The presence of ADDLs in transgenic mice with memory loss is consistent with the inference that memory recovery mediated by passive immunization with Ab-specific antibodies is due to ADDL elimination or neutralization (Klein et al., 2004).”
Amyloid β Protein: Aβ40 Inhibits Aβ42 Oligomerization
Murray, M. M., Bernstein, S. L., Nyugen, V., Condron, M. M., Teplow, D. B., & Bowers, M. T. (2009) · Journal of the American Chemical Society · doi:10.1021/ja8092604 · Cited by 128
Self-citationZhang, Y., Rempel, D. L., Zhang, J., Sharma, A. K., Mirica, L. M., & Gross, M. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309175110 · Cited by 118
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116
Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A. M., Movsesyan, N., Kiyatkin, A., Rasool, S., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4672-12.2013 · Cited by 112
“…on soluble oligomers and protofibrils of A , which are now considered to be the most toxic forms of A , responsible for causing synaptic destruction (Harper et al., 1997; Walsh et al., 1997; Lambert et al., 1998; Yong et al., 2002; Klein et al., 2004; Cleary et al., 2005; Haass and Selkoe, 2007).”
BackgroundGolde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98
Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria
Saraiva, L. M., Seixas da Silva, G. S., Galina, A., da-Silva, W. S., Klein, W. L., Ferreira, S. T., & De Felice, F. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015230 · Cited by 94
“More recently, however, new evidence has emerged demonstrating that Ab oligomers, aggregates that are soluble and much smaller than fibrils, are potent neurotoxins in AD pathogenesis [17,18], causing neuronal dysfunction at much lower concentrations than fibrillar aggregates.”
BackgroundSelf-citationTargeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“…protofibrils, actively growing fibrils, and mature fibrils that have been implicated as potential pathologic entities in AD (Selkoe, 2001a; Hardy and Selkoe, 2002; Glabe, 2005; Tanzi, 2005; Klein et al., 2004; Lesne et al., 2006; Shankar et al., 2008; Klyubin et al., 2008; Lauren et al., 2009).”
The role of APOE in transgenic mouse models of AD
Balu, D., Karstens, A. J., Loukenas, E., Maldonado Weng, J., York, J. M., Valencia-Olvera, A. C., & LaDu, M. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134285 · Cited by 81
Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Ono, K., & Yamada, M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07187.x · Cited by 76
A 2-process model for neuropathology of Alzheimer's disease
Mungas, D., Tractenberg, R., Schneider, J. A., Crane, P. K., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.007 · Cited by 58
“Tau mutations (Klein et al., 2004) and chronic traumatic encephalopathy (Baugh et al., 2012; Yoshiyama et al., 2005) are but two of the potential etiologies that require further investigation.”
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48
“…considered to be the most toxic forms of Aβ, responsible for synaptic destruction (Cleary et al., 2005; Cline et al., 2018; Haass and Selkoe, 2007; Klein et al., 2004; Lacor et al., 2007; Lambert et al., 1998; https://doi.org/10.1016/j.nbd.2020.104823 Received 1 May 2019; Received in revised…”
BackgroundInfluentialHirohata, M., Ono, K., Takasaki, J.-I., Takahashi, R., Ikeda, T., Morinaga, A., & Yamada, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.006 · Cited by 43
Tong, H., Zhang, X., Meng, X., Xu, P., Zou, X., & Qu, S. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.01.017 · Cited by 42
Nanoparticle-emitted light attenuates amyloid-β-induced superoxide and inflammation in astrocytes
Bungart, B. L., Dong, L., Sobek, D., Sun, G. Y., Yao, G., & Lee, J. C.-M. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.10.007 · Cited by 27
Gardenia jasminoides J.Ellis extract GJ-4 alleviated cognitive deficits of APP/PS1 transgenic mice
Zang, C., Liu, H., Shang, J., Yang, H., Wang, L., Sheng, C., Zhang, Z., Bao, X., Yu, Y., Yao, X., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153780 · Cited by 22
Valencia-Olvera, A. C., Balu, D., Faulk, N., Amiridis, A., Wang, Y., Pham, C., Avila-Munoz, E., York, J. M., Thatcher, G. R. J., & LaDu, M. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01375-3 · Cited by 22
Metadata
- Authors
- Klein, W. L., Stine, W. B., & Teplow, D. B.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 25
- Issue
- 5
- Pages
- 569-580
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W1996837502
- Cited by
- 483
- References
- 71
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.